Cetrorelix Dosing & Reconstitution Guide

Cetrorelix is administered via subcutaneous injection, with dosing protocols varying based on the specific research context. In studies, a daily dose of 0.25 mg is typically initiated on stimulation days 5 to 7, while a single dose of 3 mg is administered on stimulation day 7. These dosing strategies aim to optimize hormonal modulation during the follicular phase, facilitating controlled ovarian stimulation. It is important to consider that dosing regimens may differ based on experimental design and should be interpreted within the context of the specific study protocols.

Research indicates that Cetrorelix exhibits a rapid onset of action, with LH suppression observed approximately 2 to 4 hours post-administration. Peak plasma concentrations are reached within 1 to 2 hours, highlighting the compound's swift pharmacodynamic profile. The half-life varies considerably depending on the dosage, approximately 30 hours for the 3 mg dose and around 5 hours for the 0.25 mg dose. Notably, the effects of Cetrorelix can lead to same-day LH suppression, with a washout period of 3 to 5 days following the administration of the 3 mg dose. These pharmacokinetic characteristics underscore the importance of timing in relation to the follicular phase of the menstrual cycle.

For optimal preservation, lyophilized Cetrorelix should be stored at a controlled temperature of 25 °C (77 °F), with permissible excursions between 15-30 °C. Such conditions help maintain the stability and integrity of the compound during storage. Once reconstituted, Cetrorelix should be utilized immediately to ensure efficacy, as the stability of the compound may diminish over time. Adhering to these storage guidelines is critical for research applications to minimize degradation and enhance reproducibility in experimental outcomes.

In research settings, Cetrorelix is typically administered via subcutaneous injection in designated sites such as the lower abdomen and upper thigh. Selecting appropriate injection sites is essential for minimizing discomfort and ensuring accurate delivery of the compound. The choice of site may also influence absorption rates and overall pharmacokinetic profiles, which are critical considerations in the context of experimental design.

Cetrorelix has been associated with certain injection site reactions, including redness, itching, and swelling, occurring in approximately 4% of cases. Other reported adverse effects include nausea (1.3%) and headache (1.1%), indicating a relatively favorable safety profile in research contexts. However, specific contraindications must be noted, including hypersensitivity to Cetrorelix, GnRH, or any GnRH analogs, as well as mannitol. It is also contraindicated in individuals known or suspected to be pregnant or breastfeeding, emphasizing the need for careful screening in any research involving human subjects.